UnitedHealth set to snap six straight sessions of losses (UNH:NYSE)
UnitedHealth Group (UNH) shares are poised to end a six-session losing streak, rising 1.6% to $388.9 in afternoon trading. The health insurer had previously lost over 4% across the preceding six sessions, despite having risen nearly 17% year-to-date. Key drivers for UNH include strong revenue growth, positive analyst ratings, and proactive capital management, though risks such as government intervention and antitrust investigations remain.
TJX Companies Raises Full-Year Guidance After a 29% EPS Jump in Q1 2027
TJX Companies reported strong Q1 FY2027 results, exceeding Street estimates with a 9% year-over-year revenue increase to $14.32 billion and a 29% jump in diluted EPS to $1.19. All divisions showed comparable sales growth, leading management to raise full-year guidance for revenue and EPS. The company's profitability improved due to merchandise margin gains and fuel hedge benefits, though future profitability will depend on sustaining these margins amidst anticipated higher fuel costs in the second half of the fiscal year.
What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
A Sun Life U.S. report analyzing over 70,000 high-dollar medical claims reveals that secondary (comorbid) conditions, long inpatient hospitalizations, and injectable drugs are the primary drivers of medical claims exceeding $3 million. The report identifies orthopedic/musculoskeletal conditions, premature births, and cancer as common and costly conditions, with GLP-1s showing promise in reducing risks associated with high-dollar claims despite increased use. Sun Life emphasizes a whole-person care approach and offers various health support solutions to manage these rising healthcare costs.
UnitedHealth Group (UNH) – Among the 10 High Quality Stocks to Buy According to Hedge Funds
UnitedHealth Group (UNH) is listed among the top 10 high-quality stocks favored by hedge funds. Analysts from UBS and BofA recently raised their price targets on UNH, citing strong Q1 results, improved Medicare Advantage rates, and confidence in margin recovery despite ongoing cost pressures from specialty drugs and behavioral health. The company, a major healthcare and well-being provider, encompasses Optum and UnitedHealthcare segments, demonstrating a bullish outlook from its leadership.
Berkshire Hathaway Inc. Class B Trade Ideas — BVL:BRK/BUS
This article compiles various trade ideas and technical analyses for Berkshire Hathaway Inc. Class B stock (BRK/BUS). Traders present both long and short perspectives, discussing potential price movements, retracement levels, support/resistance, and fundamental analysis methods. The ideas highlight different strategies ranging from value investing to technical pattern recognition, acknowledging the stock's diverse holdings and market performance.
Third-party pixel use greatly increases healthcare data breach risk: study
A new study reveals that hospitals utilizing third-party tracking pixels are 46% more likely to experience a data breach. These pixels, common in other industries, raise significant HIPAA compliance and data privacy concerns in healthcare by transmitting sensitive patient information to external vendors. Researchers recommend that hospitals adopt homegrown, first-party tracking pixels to maintain control over data collection and mitigate the risk of unintended disclosures and security lapses.
UnitedHealth Group Incorporated stock (US91324P1021): Shares slide after Medicare and earnings press
UnitedHealth Group's stock remains volatile due to investor reassessment of growth in managed care, Medicare-related pressure, and earnings outlook. The company operates through UnitedHealthcare, its insurance platform, and Optum, which provides pharmacy and care services, giving it exposure to various aspects of the healthcare industry. While expected to grow, the stock faces risks from medical-cost trends, regulatory scrutiny, and policy changes affecting Medicare Advantage and drug pricing.
Two USPSTF leaders fired, sparking concern about panel's credibility
Two U.S. Preventive Services Task Force (USPSTF) chairs were terminated by HHS Secretary Robert F. Kennedy Jr., raising concerns among public health experts about the panel's independence and its future. This move comes as the panel has not met for over a year, has many vacant seats, and the Trump Administration has shown interest in restructuring it. Industry professionals and organizations like AcademyHealth and the American Medical Association are advocating for a transparent and unbiased process for appointing new members to protect access to free preventive services mandated by the Affordable Care Act.
UnitedHealth Group (UNH) Gains as Managed Care Outgrows Economy
Eagle Capital Management highlighted UnitedHealth Group Incorporated (UNH) in its Q1 2026 investor letter, noting its significant scale in managed care and potential for margin improvement. Despite recent struggles due to Medicare Advantage costs, the firm anticipates over 20% annual EPS growth, supported by cost reductions and AI implementation. The stock is held by 145 hedge funds, and the company reported Q1 2026 revenues of nearly $111.7 billion.
Does Amazon.com (AMZN) Have More Upside?
Amazon.com (AMZN) is positioned as a strong player in the AI landscape, primarily through its Amazon Web Services (AWS) division. AWS has seen significant growth, with revenue up 28% in Q1 2026, driven by high demand for its GPU-based cloud services and AI chips like Trainium and Inferentia. The company's Trainium chips are gaining traction by offering better price-performance compared to competitors, with newer versions nearly fully subscribed.
The Escalator: Amgen, CG Life, Cosette Pharmaceuticals and more
This article, "The Escalator," details recent personnel changes and key events across the pharma, biotech, and medical marketing industries. It highlights new hires at companies like Amgen, CG Life, and Cosette Pharmaceuticals, executive elevations within regulatory bodies, and significant board appointments. The piece also covers notable departures, miscellaneous industry news including FDA analyses, political actions, and philanthropic partnerships.
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Bristol-Myers Squibb (BMY)
Analysts from Wells Fargo and Bank of America Securities have issued bullish ratings for UnitedHealth (UNH) and Bristol-Myers Squibb (BMY), respectively. Wells Fargo maintained a Buy rating for UnitedHealth with a $397.00 price target, while Bank of America Securities reiterated a Buy rating for Bristol-Myers Squibb with a $67.00 price target. Both companies received a Moderate Buy consensus rating from analysts.
Humana (HUM) is Rebounding to a Multi-Year Improvement in Margins and Returns
Eagle Capital Management, in its Q1 2026 investor letter, highlighted Humana Inc. (NYSE:HUM), an American insurance company, despite its stock having seen significant recent gains. The firm believes Humana, along with UnitedHealth Group, is moving towards a multi-year improvement in margins and returns following a downtrend in Medicare Advantage, bolstered by cost-reduction efforts and AI implementation. Eagle Capital Management projects annual EPS growth exceeding 20% for Humana.
BMO (BMO) issues auto-callable note linked to META, NVDA, UNH with 19.40% coupon
BMO has priced an auto-callable equity-linked note due May 23, 2029, with a face value of $1,000 and a 19.40% per annum contingent coupon rate. Payments and automatic call features are tied to the performance of the lowest-performing among Meta Platforms (META), NVIDIA (NVDA), and UnitedHealth Group (UNH). Investors could lose principal if the lowest-performing Underlier falls below its 60% downside threshold, and the notes are subject to credit risk of Bank of Montreal.
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders
Humana (HUM) recently expanded its Medicare Advantage coverage for CVRx Inc.'s Barostim therapy, effective May 1, 2026, benefiting approximately 5.2 million Medicare Advantage members with eligible heart failure. This move aligns with Humana's strategy to enhance clinical quality and control costs, though regulatory shifts and existing financial uncertainties for Humana still warrant careful investor consideration. The decision is seen as supportive of advanced heart failure care, impacting Humana's investment narrative within the broader context of its financial forecasts and market valuation.
National HealthCare Corp stock hits all-time high at 199.7 USD
National HealthCare Corp (NHC) stock reached an all-time high of $199.7, reflecting an 88.62% increase over the past year. The company has raised its dividend for 12 consecutive years and recently announced the acquisition of 35 senior care facilities for $560 million. Despite appearing overvalued by some analyses, NHC's strategic moves and strong performance indicate sustained investor confidence.
Pennant Group COO: Moratorium Throws Wrench in Access Challenges
The COO of The Pennant Group, John Gochnour, expressed concerns that a new national hospice and home health moratorium, while aimed at fighting fraud, could hinder legitimate providers from expanding into underserved markets. Pennant Group, which focuses on strategic expansion in states like Alabama, Georgia, and Tennessee, had four new enrollments planned for rural, underserved communities that will now be impacted. Gochnour stressed the need for long-term regulatory solutions to ensure access to care for the aging population, especially in remote areas.
MOH News | MOLINA HEALTHCARE INC (NYSE:MOH)
This article provides recent news and analysis for Molina Healthcare Inc. (NYSE:MOH), compiling various reports from ChartMill and Zacks. The reports cover topics such as membership changes, stock performance post-earnings, and assessments of whether the stock is undervalued or a good choice for a bottom fisher.
10 Best Stocks to Buy According to Goldman Sachs “Conviction List”
This article identifies 10 top stocks from Goldman Sachs' "Conviction List," screened by short interest as a percentage of float. Goldman Sachs' list highlights compelling investment opportunities, and when combined with low short interest, it suggests strong institutional backing with limited bearish sentiment. The article details the first two stocks on the list: DoorDash, Inc. (NASDAQ:DASH) and UnitedHealth Group Incorporated (NYSE:UNH), outlining Goldman's rationale and recent financial performance for each.
Humana Just Got a Massive Upgrade From Deutsche Bank: Price Target Nearly Doubles to $441
Deutsche Bank has aggressively upgraded Humana (NYSE:HUM) to Buy, nearly doubling its price target to $441 from $235, signaling a fundamental reset and recovery for the managed care company. This upgrade, along with Mizuho's price target raise, is driven by expectations of improved Medicare star ratings and a stabilizing managed care market, despite the stock's recent sharp rally and some ongoing risks. The bank views 2026 as an earnings bottom and a re-basing year, with October's star ratings serving as a key catalyst.
Low digital health literacy hamstrings seniors' health IT use
A report from CVS Health reveals that low digital health literacy significantly impacts seniors, preventing 58% of Medicare enrollees aged 65 and older from fully managing their health. Despite this, 86% of seniors are open to using health IT, highlighting a crucial opportunity for healthcare organizations to implement human-led educational programs. The findings challenge the assumption that older adults are resistant to technology, emphasizing the need for accessible resources to bridge the digital health literacy gap.
UnitedHealth Group Incorporated stock (US91324P1021): Q1 numbers, Medicare pressure and what’s nex
UnitedHealth Group (UNH) remains a focused healthcare stock due to its latest quarterly report and the ongoing impact of the Change Healthcare cyberattack. The company reported revenue growth but also higher medical cost trends in Q1 2026. This article explores UnitedHealth’s business model, key revenue drivers, industry trends, and competitive position, highlighting its importance for US investors despite regulatory and operational challenges.
Is Alignment Healthcare’s (ALHC) Index Debut and Leadership Shuffle Reframing Its Long-Term Strategic Ambitions?
Alignment Healthcare (ALHC) recently underwent a leadership reshuffle, with founder John Kao becoming Chairman and new senior hires taking COO and MSO President roles. Concurrently, the company was added to the S&P SmallCap 600 and S&P Composite 1500, potentially increasing its investor base and visibility. These changes occur as Alignment Healthcare aims for significant revenue and earnings growth by 2029 through its tech-enabled Medicare Advantage model, though management of medical costs and regulatory risks remain critical for its profitability.
The 50 largest public companies in Minnesota, ranked
The 50 largest public companies in Minnesota experienced a 2% decline in net profits in 2025, totaling $50.5 million, despite a 6.8% increase in revenue to $861 billion. Five of the top ten companies, including UnitedHealth Group, saw lower profits, and seven of the largest companies cut jobs, contributing to an overall reduction of 43,000 employees. Despite these challenges, the market capitalization of the top 50 companies grew by 2.9%, with some companies significantly increasing stock value, offsetting UnitedHealth's 15% decline.
Mitsubishi UFJ Asset Management UK Ltd. Sells 12,000 Shares of CVS Health Corporation $CVS
Mitsubishi UFJ Asset Management UK Ltd. significantly reduced its stake in CVS Health Corporation by 75% in Q4, selling 12,000 shares and retaining 4,000 shares valued at $317,000. Despite this sell-off, CVS Health reported strong quarterly results, beating EPS and revenue estimates, and reaffirmed its FY 2026 EPS guidance. Analysts generally maintain a "Moderate Buy" rating for CVS, with several firms raising price targets.
Tecnoglass or CRH: Which Stock Has More Upside?
This article analyzes whether Tecnoglass (TGLS) or CRH (CRH) presents a better investment opportunity, concluding that TGLS offers more upside. The comparison highlights TGLS's superior revenue growth, higher operating margins, and lower valuation multiples compared to CRH. Despite having a lower win rate in monthly returns, TGLS shows a significantly higher cumulative total return since 2021.
Moratorium unlikely to hurt Addus’ M and A efforts, CEO Allison says
Dirk Allison, CEO of Addus HomeCare, stated that a new six-month Medicare enrollment moratorium for hospices and home care agencies is unlikely to affect Addus's operations or its merger and acquisition strategy. This is primarily because personal care services, which constitute the majority of Addus's business, are exempt from the moratorium. Allison also believes the government's crackdown on fraud might benefit large, compliant providers like Addus, potentially encouraging smaller agencies to sell.
Berkshire Exit Puts Spotlight On UnitedHealth Earnings Strength And Regulatory Risks
Berkshire Hathaway has fully exited its stake in UnitedHealth Group (NYSE:UNH) after less than a year, prompting investors to re-evaluate the company's risk profile, particularly concerning regulatory scrutiny and cost pressures. While some see this as a red flag, other large institutions and analysts remain positive, citing UnitedHealth's scale and efficiency efforts. This exit amplifies attention on potential downside risks despite recent strong earnings and raised guidance.
AMA taps UnitedHealth exec to head its operations
The American Medical Association (AMA) has appointed an executive from UnitedHealth to lead its operations. This move is highlighted in an article by Jon Asplund on May 19, 2026, and indicates a significant leadership change for the AMA. The article mentions the AMA's headquarters in Chicago.
[424B2] BARCLAYS BANK PLC Prospectus Supplement
Barclays Bank PLC has priced $2,956,000 of AutoCallable Contingent Coupon Notes linked to UnitedHealth Group Incorporated common stock. These notes offer a contingent coupon of $25.00 per $1,000 (10.00% p.a.) on specified observation dates and are callable if UnitedHealth's closing value meets or exceeds a call value. Investors face principal risk if the final value of the reference asset falls below the barrier value, potentially losing up to 100% of their investment, and are subject to Barclays' credit risk and potential U.K. Bail-in Power.
UnitedHealth Group Incorporated stock (US91324P1021): earnings beat and guidance focus after recent volatility
UnitedHealth Group Incorporated reported a strong Q1 2026 earnings beat and updated its full-year guidance, reassuring investors after recent market volatility. The company, a major player in managed care and health services through UnitedHealthcare and Optum, demonstrated its ability to manage medical costs and expand services. Investors are now focusing on ongoing regulatory developments and cost trends, as well as the company's dividend profile and upcoming earnings dates.
UnitedHealth Under the Microscope After Berkshire Pulls the Plug
Berkshire Hathaway has sold its entire stake in UnitedHealth Group, causing UNH shares to drop 2%. This exit, part of a broader portfolio re-shuffle under Berkshire's new CEO Greg Abel, has raised questions, although some see it as profit-taking rather than a fundamental issue with the company. Key concerns like elevated medical costs and regulatory scrutiny that Berkshire initially overlooked still persist, even as UnitedHealth's stock performance has improved year-to-date.
CVS offloads Omnicare pharmacy unit in $250m bankruptcy sale
CVS Health Corp. has received federal bankruptcy court approval for the $250 million sale of its Omnicare long-term care pharmacy subsidiary to GenieRx Holdings. This divestment is part of CVS's ongoing strategy to streamline its extensive healthcare portfolio, following other actions like job cuts in its Aetna unit. Despite these consolidations, CVS Health reported strong first-quarter financial results, with significant increases in net income and total revenue across all operating segments.
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were down on Monday, with several major stocks experiencing pre-market declines. UnitedHealth Group fell after Berkshire Hathaway diluted its position, while Regeneron Pharmaceuticals dipped following unsuccessful Phase 3 trials. Other companies like Amtech Systems, Li Auto, and Icahn Enterprises also saw their stock prices decrease.
UnitedHealth Group Incorporated Trade Ideas — LSX:869561
This article compiles various trading ideas and analyses for UnitedHealth Group (UNH) stock, ranging from long-term bullish outlooks to short-term bearish plays. Several contributors debate the stock's future based on fundamental events like a cyber-attack, regulatory probes, earnings, internal buying, and technical indicators such as RSI, MACD, and moving averages. The overarching sentiment is mixed, with some seeing a significant buying opportunity due to undervaluation and insider confidence, while others predict further downside based on persistent bearish momentum and market sentiment.
UnitedHealth (UNH) Shares Decline Following Berkshire Hathaway Exit, Reuters Reports
UnitedHealth (UNH) shares dropped over 2% after Reuters reported that Berkshire Hathaway sold its entire stake in the healthcare giant as part of a first-quarter portfolio reshuffle. The exit followed an initial investment last August that had previously boosted investor confidence. Despite this, a Bank of America analyst recently raised their price recommendation for UNH, citing a "bullish" outlook from the company's leadership team regarding future target margins.
Enhabit names new CEO
Enhabit Inc., a home health and hospice provider recently acquired by Kinderhook Industries, has appointed Dale Clift as its new president and CEO. Clift succeeds Barb Jacobsmeyer, who had announced her departure last August. Kinderhook Industries expressed confidence in Clift's leadership経験 to guide Enhabit's continued growth and patient care expansion.
Boston Scientific Corp Stock (BSX) Closed Up by 5.88% on May 18: Facts Behind the Movement
Boston Scientific Corp (BSX) stock closed up by 5.88% on May 18, driven by a strategic $1.5 billion investment in MiRus LLC, including an option to acquire its TAVR business. Further boosting investor confidence, the company initiated a $2 billion accelerated share repurchase agreement following strong Q1 2026 financial results that surpassed expectations. These actions, coupled with reaffirmed "Buy" or "Outperform" ratings from analysts, contributed to the significant upward movement despite some technical indicators suggesting caution.
Following Buffett: Greg Abel Cuts Berkshire Holdings Dating Back To 2011 — But The Big Names Stay Put
Berkshire Hathaway's first 13F filing under new CEO Greg Abel revealed significant portfolio adjustments, including the full exit of positions like Visa and Mastercard, which dated back to 2011. While some core holdings were reduced or exited, the top 10 holdings largely remained consistent with Warren Buffett's previous tenure, with notable increases in Alphabet Class A shares and unchanged positions in Apple, American Express, Coca-Cola, and Moody's. The company also introduced new positions in Delta Air Lines, Macy's Inc, and Alphabet Class C.
Health systems delay EHR purchases amid uncertainty, rising AI investment
A KLAS Research report shows a significant drop in acute care EHR purchase decisions by health systems in 2025, down 40% from 2024, as organizations prioritize immediate financial returns through investments in AI and operational efficiency tools. The report highlights Epic Systems' continued market expansion, adding 77 hospitals, while Oracle Health lost 56 hospitals and faces pressure to restore customer confidence amid declining satisfaction with its Millennium EHR and pending AI-enabled platform rollout. Smaller vendors like MEDITECH saw strong retention, with 84% of legacy customers migrating to its Expanse platform despite ongoing interoperability concerns.
Humana Just Ripped 48% in a Month. Is It Outperforming Other Healthcare Stocks Like UnitedHealth and Cigna?
Humana (HUM) stock has surged 48% in the past month, outperforming UnitedHealth Group (UNH) and Cigna Group (CI), largely due to favorable Medicare Advantage rates and strong Q1 2026 results. Humana's concentrated exposure to Medicare Advantage has allowed it to benefit more significantly from recent regulatory tailwinds. While analysts have raised price targets for Humana, some suggest the stock may be overvalued, noting that the recent rally could be a recovery from a multi-year drawdown rather than the start of a new bull market.
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know
Abbott Laboratories (ABT) stock increased by 3.04% on May 18, driven by positive Q1 2026 financial results that surpassed analyst estimates and reaffirmed full-year guidance. The recent $23 billion acquisition of Exact Sciences is expected to significantly strengthen its position in the cancer diagnostics market, contributing to investor confidence alongside strong performance in its Medical Devices segment and consistent shareholder returns. Despite technical indicators showing mixed signals and some analyst concerns about dilution and organic growth, institutional investors have increased their holdings, and the consensus remains a "Buy."
Intuitive Surgical Inc Stock (ISRG) Moved Up by 3.76% on May 18: A Full Analysis
Intuitive Surgical Inc. (ISRG) stock increased by 3.76% on May 18th, driven by strong Q1 2026 financial results, which reported $2.77 billion in revenue and a 23% year-over-year increase. The company also raised its 2026 procedure guidance due to the success of its da Vinci 5 platform. Analysts maintain a "Moderate Buy" rating with a consensus price target of $583.45, reflecting positive market sentiment despite some technical indicators suggesting caution.
The 'corporate takeover' of physician practices accelerates: study
A new report by Avalere Health for the Physicians Advocacy Institute reveals a significant acceleration in the corporate acquisition of physician practices, with over four in five U.S. physicians employed by hospitals, health systems, or corporate entities by the end of 2025. This trend, termed a "corporate takeover," has reduced the number of physicians in physician-owned settings to just 18% and is impacting clinical autonomy and patient care. While consolidation offers some physicians better work-life balance and higher pay, it raises concerns about corporate interference in medical decision-making and the long-term viability of independent practices.
Jim Cramer Reveals Why Broadcom (AVGO) Is Powerful
Jim Cramer highlighted Broadcom (AVGO) as a powerful company with silicon desired by many, indicating it's still cheaply valued despite significant share price increases. Citi analysts also raised their price target for Broadcom, citing strong AI demand as a tailwind for potential robust April quarter results. The company's CEO, Hock Tan, was also commended by Cramer for his prowess.
Why Is UnitedHealth Stock Trading Lower On Monday?
UnitedHealth Group (UNH) stock is trading lower on Monday due to Berkshire Hathaway's reported divestment of its entire stake in the company, a move attributed to a portfolio realignment led by Greg Abel. Separately, UnitedHealth is intensely focused on AI integration, tracking employee AI usage across its Optum division and investing significantly in AI initiatives, citing substantial operational gains and strong first-quarter financial results.
UnitedHealth falls after Berkshire sells stake in health insurer
UnitedHealth (UNH.N) shares dropped 3% after Berkshire Hathaway (BRKa.N) revealed it had sold its stake in the healthcare conglomerate during the first quarter. This sale, part of a portfolio reshuffling under CEO Greg Abel, comes after Berkshire had invested in UnitedHealth last year, causing an initial stock increase. Despite the market reaction, analysts believe UnitedHealth's ongoing operational turnaround remains promising, especially following its recent raised profit forecast and strong quarterly earnings.
UnitedHealth Group (UNH) Fell 33% as Rising Medical Costs and Member Mix Pressured Earnings
UnitedHealth Group (UNH) experienced a 33% decline in 2025, primarily due to higher-than-expected medical costs and an unfavorable member mix. Latitude Investment Management, in its Q4 2025 investor letter, highlighted that medical cost trends were 7.5% compared to the budgeted 5%, resulting in a significant earnings shortfall. Additionally, new members from weaker peers exhibited worse health attributes, further impacting the company's financial performance.
Most older Americans say low digital literacy harms health
A CVS Health study revealed that 58% of Medicare-eligible older Americans believe low digital literacy negatively impacts their health management, with 85% struggling to navigate digital health platforms. However, 86% are open to using these tools, and 71% desire more engagement. CVS Health is addressing this gap through a $20 billion technology investment focused on intuitive tools, personalized care paths, and community-based education to improve accessibility and support for this growing, complex population.
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were down on Monday, with the Nasdaq futures falling around 100 points. Several large-cap stocks experienced significant drops in pre-market trading, including UnitedHealth Group, Regeneron Pharmaceuticals, and Li Auto, primarily due to company-specific news or broader market sentiment. Each company's decline was attributed to factors like Berkshire Hathaway's divestment, unsuccessful clinical trials, or previous day's performance.
